Accessing Library
Connecting to Pep Nation Lab's research database...
Connecting to Pep Nation Lab's research database...
Select Up To Four Compounds To Review Their Evidence, Targets, And Handling Side By Side.
For Laboratory Research Only
| Attribute | ||
|---|---|---|
Research Summary | AOD-9604 is a tiny piece of human growth hormone that only does one job: it tells the body to burn stubborn fat. It ignores everything else, so it won't make you hungry or mess with your blood sugar. | This is literally just the fat-burning piece of human growth hormone cut off from the rest. Because it is only the fat-burning piece, it burns fat rapidly without causing muscles to grow or affecting your blood sugar. |
Studied For | Obesity / fat-metabolism researchLipolysis / fat burningAdipose tissue reductionBody fat reduction without IGF-1 elevationVisceral fat lossSubcutaneous fat reductionWeight managementMetabolic syndrome researchFat-loss peptide researchNon-GH lipid metabolismCarbohydrate metabolismAnti-obesity researchBody composition improvementAbdominal fat reductionFat oxidation enhancementweight lossfat burningstubborn fatcartilage repairosteoarthritis | Lipolysis / fat lossAdipose reductionVisceral fat reductionBody composition improvementSubcutaneous fat burningFat oxidationAnti-obesity researchWeight managementMetabolic rate enhancementFat-loss peptide researchAbdominal fat researchBeta-3 adrenergic lipolysisLean mass preservation during fat lossGH-fragment weight research |
Research Areas | MetabolicWeight Management & Fat LossPerformance & Muscle | MetabolicWeight Management & Fat Loss |
Best Stacked With | hgh-fragment-176-191l-carnitinelipo-cbac-watersemaglutide | aod9604l-carnitinelipo-cbac-water |
Overview | ||
Category | Weight Loss & Metabolism | Muscle Growth & Performance |
Compound Class | Modified C-terminal growth-hormone fragment (hGH 177-191) | Synthetic fragment of HGH C-terminus (residues 176-191) |
Molecular Target | Lipolysis via beta-3 adrenergic and lipase pathways; no GH receptor binding; no IGF-1 elevation | Beta-3 adrenergic receptors; stimulates lipolysis without GH receptor binding; no IGF-1 elevation |
Aliases / AKA | AOD 9604AOD-9604Tyr-hGH 177-191hGH fragment 177-191HGH fragment 177-191Anti-obesity drug 9604 | HGH FragAOD FragmentFrag 176-191HGH FragmentFragment 176-191HGH 176-191 |
Parent Compound | Human growth hormone fragment | Human growth hormone |
Molecular Weight | 1815.1 Da | 1817.1 Da |
Amino Acid Sequence | GH 176-191 with N-terminal Tyr (16 aa) | 16-aa C-terminal lipolytic fragment of human growth hormone (residues 176-191) |
CAS Number | 221231-10-3 | 66004-57-7 |
Year Discovered | Not Listed | Not Listed |
Pro-Angiogenic | No | No |
GLP-1 Class | No | No |
Purity | Not Listed | Not Listed |
Identity | ||
Evidence Tier | ||
Risk Level | ||
PubMed Citations | 785 Good | 23 Sparse |
Clinical Trials | Not Listed | Not Listed |
Regulatory Status | Not FDA-approved (development halted); WADA-banned. | Not FDA-approved; research chemical; WADA-banned. |
Evidence & Regulatory | ||
Half-Life | ~3 minutes | ~3 minutes |
Typical Frequency | Not Listed | Not Listed |
Administration Route | Injection Only | Injection Only |
Mechanism / PK | Not Listed | Not Listed |
Reported Findings | Obese-mouse studies show weight reduction. Important: the pivotal human Phase 2b obesity trial failed its primary endpoint and development was discontinued. Net human weight-loss efficacy is negative. | Obese-mouse studies show reduced weight and increased fat oxidation. Human evidence for the fragment is minimal; most human data come from the related AOD9604, which was ultimately not significant. |
Side Effects Noted | Generally well tolerated in human trials at studied oral doses; long-term and injectable safety uncharacterized. | Limited formal human safety data; mainly injection-site reactions in unregulated use; long-term safety uncharacterized. |
Warnings | Failed its pivotal trial; not an approved medicine; a self-affirmed food-additive determination is not FDA drug approval. WADA-banned. Research use only. | Not approved; human efficacy unproven; grey-market identity and purity are a major limitation. WADA-banned. Research use only. |
Pharmacology | ||
Form | lyophilized | lyophilized |
Diluent | bacteriostatic water; gentle, no foaming | bacteriostatic water; slow, no foaming |
Storage Temp | -20C, dark | -20C, dark |
Light Sensitive | Yes | Yes |
Freeze / Thaw | avoid | avoid |
Handling Notes | Was also formulated orally. | Disulfide loop is oxidation-sensitive. |
Reconstituted Shelf Life | 28 Days Refrigerated | 28 Days Refrigerated |
Handling & Storage | ||
Pep Nation Lab's comparison tool puts research-grade peptides and compounds head to head - mechanism of action, molecular target, evidence tier, molecular weight, sequence, half-life, and documented research focus - so qualified researchers can evaluate the differences that matter. Every data point is drawn from a referenced monograph. For in vitro laboratory research use only.
The two most-studied research peptides for tissue repair and recovery.
Single GLP-1 versus dual GLP-1/GIP incretin agonists in metabolic research.
Dual versus triple incretin receptor agonists in weight-research models.
A GLP-1 agonist versus a triple-agonist incretin in metabolic research.
A GHRH analog versus a selective ghrelin-receptor secretagogue.
A ghrelin-receptor secretagogue versus a GHRH analog for growth-hormone research.
Two GHRH analogs studied on the growth-hormone axis.
The two first-generation growth-hormone releasing peptides.
An amylin analog versus a GLP-1 agonist in metabolic research.
A mitochondrial-derived peptide versus an HGH fragment in metabolic research.
Melanocortin versus kisspeptin pathways in reproductive research.
A telomerase-pathway peptide versus NAD+ metabolism in longevity research.
A potent versus a highly selective ghrelin-receptor secretagogue.
Two GHRH analogs with contrasting half-life profiles.
A direct IGF-1 analog versus a growth-hormone secretagogue.
The DAC versus non-DAC forms of the CJC-1295 GHRH analog.
Two Russian-developed nootropic and anxiolytic research peptides.
Two mitochondrial-targeted peptides in cellular-energy research.
Two immune-modulating research peptides with distinct mechanisms.
Two HGH-fragment analogs studied for fat-metabolism research.
Next-generation multi-receptor incretin agonists in metabolic research.
Browse the full research catalog or the A To Z index to compare any compound.
Any research-grade compound in the library can be placed side by side - up to four at a time. The tool compares mechanism of action, molecular target, evidence tier, molecular weight, amino acid sequence, reported half-life, and what each compound has been studied for, all drawn from referenced monographs.
The evidence tier reflects how extensively a compound has been studied in the referenced literature, from early preclinical signals through to compounds with human clinical data. It is a research-quality signal only, never a safety or efficacy endorsement.
Each comparison page is generated from the same referenced compound database - a genuine side-by-side of mechanism, identity, pharmacokinetics, and evidence, plus data-derived key differences. They are curated, not auto-generated thin pages.
No. Every comparison is for in vitro laboratory research use only. Nothing here is medical advice, a treatment recommendation, or dosing guidance, and no product is for human or animal consumption.
